Hengrui Pharmaceutical announced that it has received a full response letter from the US FDA regarding injectable carelizumab.
恒瑞医药：收到美国FDA关于注射用卡瑞利珠单抗的完整回复信
Hengrui Pharmaceutical: Received a complete response letter from the US FDA regarding injectable carelizumab
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.